ABSTRACT A patient with far-advanced adult type Gaucher's disease was treated with solubilized, highly purified placental glucocerebrosidase administered after entrapment in human erythrocytes or by direct intravenous injection. In some instances the enzyme-containing erythrocytes were coated with gamma globulin. No toxic side effects were observed after enzyme infusion. There were suggestive, but not conclusive, findings that enzyme infusion may have been beneficial. After therapy, there was a decrease in transfusion requirement, some improvement of liver function, possible decrease in liver size, and relief of subjective symptoms. Erythrocyte and plasma glucocerebroside levels were unchanged during therapy, but there was a possibly significant decrease in leukocyte and platelet levels of the glycolipid. No changes occurred in serum acid phosphatase or angiotensin-converting enzyme activity.
Gaucher's disease is a glycolipid storage disorder in which glucocerebroside accumulates in phagocytic cells throughout the body. A rare disease in most population groups, this autosomal recessive disorder has a frequency of between 1 in 5000 and 1 in 10,000 among Jews of Eastern European origin. Clinical features include massive hepatosplenomegaly, bone marrow failure, and bone pain and fractures. The central nervous system is spared in the adult form of the disease. Because storage occurs primarily in the reticuloendothelial system, patients with Gaucher's disease have been considered among the most suitable candidates for enzyme replacement therapy (1, 2) . Pentchev et al. (3) achieved about 4100-fold purification of detergent-solubilized glucocerebrosidase from human placenta with a yield of 5%. They infused the partially purified enzyme into three patients and detected a transient decline in erythrocyte glucocerebroside levels (4, 5) . Liver biopsies taken before and after enzyme infusion seemed to show a modest decline in liver glucocerebroside content. We have recently succeeded in solubilizing detergent-free glucocerebrosidase and in purifying the enzyme 6000-to 8000-fold with a yield of 40-60% (6, 7), and we now report clinical and laboratory observations in a patient with far-advanced Gaucher's disease whom we have treated with this enzyme.
MATERIALS AND METHODS
Glucocerebrosidase was purified from human placenta by previously described methods or minor modifications thereof (6) of glucocerebrosidase activity is not applicable to the highly purified enzyme used in these studies: detergents that stimulate insoluble preparations inhibit the highly purified enzyme. However, 1 unit of our preparation probably corresponds to between 2 X 104 and 2 X 105 units of theirs. In some studies the enzyme was incorporated into normal human erythrocytes by adding enzyme to erythrocytes packed at a hematocrit value of 70%, dialyzing against 5 mM phosphate buffer, pH 7.4, for 2 hr at 40, and then dialyzing against buffered saline at 250 (8) .
For the estimation of glucocerebroside levels, erythrocyte preparations were freed of leukocytes by filtration through microcrystalline cellulose-a-cellulose (9) . Leukocytes and platelets were separated into platelet-rich, granulocyte-rich, monocyte-rich, and lymphocyte-rich fractions (10) . Glucocerebroside assays were carried out by high-pressure liquid chromatography with a modification of the method described by Evans and McCluer (11) . A chloroform/methanol, 2:1 (vol/vol), extract of plasma or blood cells was dried under nitrogen, benzoylated with 0.6 ml of 50% benzoyl chloride in dry pyridine, and dried under nitrogen. After redissolving in hexane, it was washed six times with alkaline, acidic, and unmodified methanol, dried under nitrogen, redissolved in hexane, and chromatographed on a Corasil I column with a linear gradient of 0-0.75% or 0-1.00% methanol in hexane.
Patient. The patient was a Jewish woman, born in 1944, who was known since age 5 to have Gaucher's disease. Details of her clinical history were published in 1973 (1) . During the past few years she had had a gradual downhill course, with chronic arterial hypoxemia secondary to pulmonary shunting and repeated episodes of fever, infection, and life-threatening bleeding from her nose and rectum. Her outlook was considered to be grave in early 1976 when these studies were initiated. The therapeutic trials were undertaken only after detailed explanation of the procedure and-possible risks to patient and family, and after approval by the institutional review committee. The patient was given five courses of enzyme as summarized in Table 1 . Resealed erythrocytes that had not been coated with gamma globulin were cleared quite slowly from the circulation (12) . After coating with gamma globulin the half-life (51Cr) of the cells was only 4.8 hr. Enzyme infused directly into the circulation was cleared from plasma with a half-life of approximately 19 min.
Two months after conclusion of these trials, the patient had another episode of profuse nasopharyngeal hemorrhage. Bleeding could not be controlled surgically or by infusion of fresh-frozen plasma and the patient died.
RESULTS
Side Effects. Enzyme infusion had no effect on pulse, blood pressure, respiratory rate, or body temperature. No subjective symptoms were associated with enzyme infusion. Measurement
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The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. Liver Function. The mean (+SEM) serum glutamate-oxaloacetate transaminase value gradually fell from a pretreatment level of 124.8 + 8.6 units/ml (n = 4) to 97.6 + 2.8 units/ ml (n = 7) (normal = 10-40 units/ml). The mean (+SEM) serum glutamate-pyruvate transaminase value fell from 30.0 + 2.9 units/ml (n = 4) before treatment to 21.6 ± 1.2 units/ml (n = 7) after treatment (normal = 5-35 units/ml). Results of clotting factor studies remained essentially unaltered.
Liver Size. Liver size as determined by external palpation appeared to regress after the second course of therapy (Fig. 1) . However, no further decrease in liver size could be established after additional courses of therapy, and the reliability of external measurements of liver size is low when the liver is massively enlarged. Measurement of liver size by technetium-99m sulfur colloid scintigram and by ultrasound suggested that a decrease of about 1 cm in each dimension occurred after the conclusion of the last course of therapy. Moreover, serial technetium scintigrams of the liver (Fig. 2 ) appeared to show improvement in an area of decreased uptake that had been present for at least 8 years. Spider hemangiomata showed a distinct decrease during the period of observation. (13) . The administration of bacterial dextranase to dextran-loaded rats suggests that exogenously infused enzyme may hydrolyze an otherwise unmetabolizable storage material in the liver (14) . The data gleaned from the studies of other enzymes are not necessarily applicable to f3-glucosidase. In the case of some lysosomal enzymes, evidence derived from fibroblast uptake suggests that the enzyme may even exist in different forms in different organs and that some are readily taken up and others are not (15) . One instance of glucocerebroside storage disease was found at autopsy in a dog (16) ; however, animal models suitable for study do not currently exist. Model systems for the study of uptake of f3-glucosidase are difficult to implement; preliminary studies in our laboratory suggest that a small amount of partially purified glucocerebrosidase is incorporated into Gaucher's disease monocytes. Another possible model system relies on the wellknown capacity of monocytes to ingest gamma globulin-coated particulates; in fact, we have found that resealed erythrocytes loaded with glucocerebrosidase and coated with gamma globulin are rapidly ingested by monocytes in vitro.
Such findings encouraged us to initiate replacement therapy with glucocerebrosidase. In the final analysis, clinical efficacy can be evaluated only in clinical trials. Appraisal of efficacy is difficult, however, especially in a patient with far-advanced density may be due to differences in technique. However, some improvement in the area of decreased uptake in the midportion of the liver and a decrease in overall liver size seemed to occur. Subjective Changes. Gradual improvement was observed in the patient's activity status and in her feeling of well-being during her treatment. Her family was quite convinced that she was considerably improved. Always difficult to appraise, subjective changes in this patient were particularly difficult to evaluate because of various perturbing factors such as infections, changing levels of hemoglobin, and intermittent episodes of nasal bleeding.
Glucocerebroside Determinations. Plasma, erythrocyte, leukocyte, and platelet glucocerebroside levels showed no consistent alteration during the first four courses of enzyme therapy. During the last course of therapy, when the largest amount of enzyme was infused, minor decreases in levels of blood cell glucocerebroside were documented (Fig. 3) ; unfortunately, only two estimations of leukocyte glucocerebroside levels could be carried out because of the large quantity of blood 
